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Western blots of olT3-1 cell extracts were immunostained with antibodies pecific for various protein kinase C (PKC) isoforms. These revealed the 
presence of PKC types a, E and c, but j?, y, 6 and r] were not detected. The potency with which partially-purified cytosolic PKC from aT3-1 cells 
was activated by phorbol 12,13-dibutyrate (PDBu), mezerein and 1,2-dioctanoyl-sn-glycerol was assessed in the presence and absence of Ca”. The 
inhibitors staurosporine, K252a, H7, GF109203X and Ro 31-8220 were tested on basal activity, PDBu-induced activity and Ca” + PDBu-induced 
kinase activity. Each inhibitor showed distinct differences in their I& values under the three conditions, su~~ting that these inhibitors may exhibit 
different potencies on the PKC isoforms present in czT3-1 cells. Although histone 111s was used as the phosphate acceptor for most of these 
experiments, the efficiency of a, E and 5 peptide and GS peptide substrates were also determined, with E peptide giving the greatest activity in the 
presence of PDBu or Ca2+. Each substrate displayed a different pattern of activation under the conditions tested. Overall, the findings suggest hat 
3 or more PKC isoforms with varying specificities are present in gonadotroph-derived aT3-1 cells and that the contribution of each isoform should 
be considered when these cells are used in models of anterior pituitary cell function where PKC is involved. 
Protein kinase C isoform; Gonadotroph; aT3-1 cell; Phorbol ester; Dia~ylgly~ro~ PKC inhibitor 
1. INTRODUCTION 
The aT3-1 gonadotroph-delved cell line was recently 
generated by targeted oncogenesis: the Simian virus-40 
(SV40) T antigen was fused to the promoter for the 
common a-subunit of the pituitary glycoprotein 
hormone family (which includes luteinizing hormone 
(LH) and injected into mouse eggs to form transgenic 
mice. One of the tumours that subsequently developed 
gave rise to the &T3- 1 cell line [ 11. As the only clonal cell 
line of a gonadotroph type, the aT3-1 cell is a poten- 
tially valuable model of the function of gonadotrophs 
within the pituitary. The LH-releasing hormone 
(LHRH) receptor induces phospholipase C-dependent 
cleavage of phosphatidylinositol bisphosphate to pro- 
duce inositol trisphosphate and diacylglycerol [2,3] 
which can lead to release of intracellular Ca2+ [4] and 
activation of PKC, respectively. Although there is some 
debate as to the role of PKC in mediating LHRH- 
induced LH release (see [S] for review), phorbol esters 
can certainly induce gonadotrophin release [68] and 
PKC inhibitors can prevent the phenomenon of LHRH 
priming whereby exposure of gonadotrophs to LHRH 
increases their subsequent responsiveness to secre- 
tagogues [9]. 
The purpose of this study was to characterise the 
isoforms and properties of PKC present in (rT3-1 cells. 
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Immunoblotting techniques were used to identify which 
individual PKC isoforms [IO,1 11 were present in these 
cells. The characte~stics of PKC activity in oir3-1 cells 
were assessed by a mixed micelle, histone 111s thio- 
phosphorylation assay that allowed separation of basal 
and activator-induced activity [12]. In addition, activity 
was examined in the presence and absence of Ca2+ in 
order to segregate the actions of classical calcium-de- 
pendent (cPKC) and novel calcium-inde~ndent 
(nPKC) PKC isoforms [13]. These experiments were 
carried out using histone 111s as the thiophosphate ac- 
ceptor as this displays clear Ca2”-dependence with the 
cPKCs 1141. Finally we investigated the effects of a 
range of PKC inhibitors on the components of kinase 
activity and also tested a number of substrates under 
different conditions of PKC activation. 
2. MATERIALS AND METHODS 
2.1. ~rnrn~oblott~g with ~t~~d~es to PKC isoforms 
trT3-I cells were grown to confluence in a 24-well plate and prepared 
for SDS-PAGE: the medium was removed and 200 ~1 of lysis buffer 
(5 mM Tris-HCI, pH 7.2,2% w/v SDS, 5% v/v 2-mercaptoethanol) at
100°C was added to each well. After scraping and trituration, the 
cell/buffer mixture was heated to 1OO’C for 5 min and undissolved 
material removed by centrifugation for 2 min at 8000 x g, 20°C. 
Alternatively, eluates from DE52 columns loaded with cell cytosol 
were boiled in the presence of 2% W/Y SDS and 5% v/v 2-mercap- 
toethanol. One yl of these extracts was loaded onto 7.5% homogene- 
ous microgels, and SDS-PAGE and electroblotting onto polyvi- 
nylidene difluoride membranes (Immobilon-P, Millipore, Watford, 
67 
Volume 333, number 1,2 FEBS LETTERS October 1993 
Herts) were performed on a PhastSystem apparatus (Pharmacia Bio- 
tech, Milton Keynes, Bucks). PKC isoforms were identified with rab- 
bit polyclonal antisera (2 &ml) raised to isoform-specific peptide 
sequences in a, j?, 6, E and [ (Gibco BRL, Paisley, Renfrew; or pre- 
pared as described by Strulovici et al., 1989; 1991 [l&16]). Antibodies 
to the same isoform from different sources gave essentially similar 
results. The PKC-q was a kind gift from Dr. Harald Mischak (NIH, 
Bethesda, MD, USA). The specificity of staining was confirmed with 
antiserum blocked by preincubation with the relevant antigenic pep- 
tide (1 ,@ml). Visualisation of the antibody reaction was achieved 
with horseradish peroxidase-labelled anti-rabbit IgG (I:5000 dilution; 
Scottish Antibody Production Unit, Carluke, Lanarks) or with protein 
A-horseradish peroxidase (Calbiochem, San Diego, CA, USA) fol- 
lowed by an enhanced chemiluminescence d tection system (ECL; 
Amersham, Aylesbury, Bucks). Brain and lung tissue from adult male 
Sprague-Dawley rats were used as positive controls for the various 
isoform specific antibodies. 
oratories, Calbiochem-Novabiochem, Nottingham. Mezerein and 
PDBu were kept as stock solutions (1 mM) in dimethylformamide 
(DMF) at -2O’C and diluted in Tris/EGTA buffer to the required 
concentration on the day of the assay. The diglyceride, l Zdioctanoyl- 
m-glycerol (DOG), was purchased from Sigma and made up as a stock 
solution of 100 mM in DMF, diluted in DMF and added to the assay 
tubes in a volume of 1 ~1. Dimethyl formamide was included in the 
control tubes containing no DOG. The stock solutions were kept at 
-20°C for no longer than 1 week. 
The PKC inhibitors [9,22], staurosporine, K252a, bisindolylmalei- 
mide (GF109203X), I-(5-isoquinoline sulphonyl)-2-methyl-piperazine 
hydrochloride (H7) were purchased from Calbiochem. Ro 31-8220 
was a gift (Roche Products, Welwyn, Herts). All but H7 (stock solu- 
tion 10 mM in H,O) were kept as stock solutions in DMF at 1 mM 
at -20°C. 
2.2. Cytosolic PKC activity assay 3. RESULTS 
Protein kinase C activity partially-purified from the cytosolic com- 
partment was measured as the phosphatidylserine (PS)-dependent his- 
tone 111s kinase activity induced by a diterpene or diglyceride using 
methods modified from those of [ 171 and [ 181 and described by us [19]. 
aT3-1 cells were grown in DMEM containing Na-pyruvate (0.11 g/l), 
penicillin/streptomycin (100 U/ml each) and 10% foetal calf serum. 
Confluent aT3-1 cells were washed then harvested by scraping into 
ice-cold buffer (20 mM Tris-HCl, pH 7.5) containing 50 mM 2- 
mercaptoethanol, 2 mM EDTA, 1 mM phenylmethylsulphonyl fluo- 
ride, 0.01% (w/v) leupeptin (Sigma, Poole, Dorset) and 20 PM trum- 
epoxysuccinyl-L-leucylamido(4-guanidino)-butane (Sigma). The cell 
suspension was homogenised using an Ystral homogeniser (Scientific 
International Industries, Loughborough, Leics), centrifuged 
(16,000 x g, 20 min, 4°C) and the supematant collected and recentri- 
fuged (16,000 x g, 5 min, 4°C). The supematant from the second spin 
was taken to represent cytosol and the PKC present was partially 
purified by ion exchange on a DE52 diethylaminoethyl cellulose ma- 
trix (Whatman International Ltd., Maidstone, Kent) at 4°C. The 
column was washed before the partially- purified PKC was eluted with 
buffer containing 150 mM NaCl. Partially-purified cytosolic PKC 
activity was measured in an assay mixture containing (final concentra- 
tions): 10 mM MgCl,, 200 &ml PS (sodium salt; Lipid Products, 
Nutfield, Surrey) + 0.04% Nonidet P40 (Calbiochem-Novabiochem, 
Nottingham, Notts), 50 PM [y-?S]ATP (NEN, 0.18 &i/tube), cytosol 
(diluted 1:5 or 1:4 final) and one of the following substrates: 1.25 
mg/ml histone 111s (Sigma), 50 PM a peptide (Arg-Phe-Ala-Arg-Lys- 
Gly-Ser-Leu-Arg-Gln-Lys-Asn-Val), 50 PM E peptide (Glu-Arg-Met- 
Arg-Pro-Arg-Lys-Arg-Gln-Gly-Ser-Val-Arg-Arg-Arg-Val), 100 PM 
GS peptide (Pro-Leu-Ser-Arg-Thr-Leu-Ser-Val-Ala-Ala-Lys-Lys) 
(Bachem Ltd, Saffron Walden, Essex) or 50 PM c peptide (Ileu-Tyr- 
Arg-Arg-Gly-Ser-Arg-Arg-Trp-Arg-Lys-Leu) (Department of Bio- 
chemistry, Nottingham University). These peptide substrates are util- 
ised better by some PKC isoforms than by others [20,21]. Assay tubes 
also contained either 600 PM CaCl, (100 PM free Ca”) or 5 mM 
EGTA (< 3 nM free Ca”). All assay components and drugs added to 
the reaction mixture were dissolved in 20 mM Tris-HCl (pH 7.5) + 0.5 
mM EGTA, and the total assay volume was either 50 ~1 or 100 ~1. 
Reactions were performed at 30°C for 15 min and were stopped by 
quenching with ATP (20 mM final) in EDTA (pH 7.0, 20 mM final) 
for the histone substrate or by addition of TCA (6.8% w/v final) for 
peptide substrates. The TCA-precipitable material was removed by 
centrifugation after incubation on ice for 20 min. The quenched reac- 
tion mixture or TCA supematant was spotted onto a 4 cm2 piece of 
P-S 1 cellulose phosphate ion-exchange chromatography paper (What- 
man International Ltd.) and washed (3 x 10 ml, 2 min, room temper- 
ature) with 75 mM H,PO,, dried and counted by liquid scintillation. 
Curve fitting of data obtained in the kinase assay was carried out using 
the non-linear error-weighted program, P.FIT (Biosoft, Cambridge). 
3.1. Immunoblots of PKC isoforms 
In order to discover which isoforms of PKC might be 
present in aT3-1 cells (and which might be responsible 
for the activities described below), Western blots of 
whole cell extracts were immunostained with antibodies 
specific for individual isoforms. PKC types a, E and 5 
were found to be present in aT3-1 cells, but p, y, 6 and 
?,J were not detectable (although, as positive controls, the 
antibodies specifically stained blots of other tissues - 
Fig. la): 
The specificity of staining of types CX, E and c was 
confirmed in whole cell extracts and in eluates from 
DE52 columns loaded with cell cytosol (Fig. lb): note 
that PKCC was often resolved as a specific doublet of 
88 and 79 kDa, the higher molecular mass form being 
stained more strongly than the lower. Results from 
other studies [23] have suggested that the higher molec- 
ular weight species may be the result of cross-reaction 
with another PKC isoform. The observed molecular 
masses of PKC types a and E were 87 and 91 kDa 
respectively (Fig. lb). 
3.2. Properties of PKC activity 
3.2.1. Kinase activators 
2.3. PKC activators and inhibitors 
The diterpenes PDBu and mezerein were purchased from LC Lab- 
The effects of several activators of PKC on the cy- 
tosolic activity in aT3-1 cells are shown in Fig. 2. In the 
absence of Ca2’, mezerein was more potent than PDBu 
at evoking PS-dependent histone kinase activity (EC,,: 
0.112 ? 0.011 yM compared with 0.313 + 0.065 PM). 
Indeed mezerein in the absence of Ca2’ could elicit al- 
most as much activity as PDBu in the presence of Ca2’. 
When Ca2’ was included in the assay, PDBu and mez- 
erein were virtually equipotent (ECSo: 0.076 f 0.016 PM 
and 0.054 ? 0.017 PM, respectively). In the absence of 
Ca2’, DOG was able to elicit 65 + 4% of maximal activ- 
ity (as seen with 3 PM PDBu + Ca2’), similar to the 
fractional activation seen with PDBu in the absence of 
Ca2+ (i.e. 62 ? 5%). The EC,, value for DOG in the 
absence of Ca2’ (22.0 f 3.5 PM) revealed a greater po- 
tency of DOG than we have observed in other tissues 
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such as brain and spleen (41-85 PM). In the presence 
of Ca*+, DOG was more potent (EC,,: 6.9 f 2.3 PM) 
than we have reported on spleen or COS 7 cells (17-18 
PM), but slightly less potent than on midbrain 
(2.1 ? 0.4 PM) [24]. 
3.2.2. Kinase inhibitors 
Staurosporine was the most potent inhibitor of 
PDBu-evoked activity in the absence of Ca2’, closely 
followed by Ro 31-8220 and GF 109203X (Table I). 
Several of the other inhibitors showed striking differ- 
ences in their I&, values for the different components 
of kinase activity. Thus K252a was relatively effective 
on basal activity (PS alone) but was a poor inhibitor of 
PDBu-evoked activity in the absence of Ca*‘. This was 
in contrast to each of the other inhibitors which were 
less potent inhibitors of basal activity compared with 
PDBu-evoked activity. H7, Ro 31-8220 and GF 
109203X were most potent on the PDBu+Ca*’ compo- 
nent of the activity. 
ther the characteristics of aT3-1 cell cytosol kinase ac- 
tivity. Fig. 3 shows a comparison of the thio- 
phosphorylation activity resulting when 01 peptide, E 
peptide, 6 peptide, GS peptide or histone 111s were used 
as substrate. Basal activity (in the presence of PS) was 
significantly inhibited by H7 using histone IIIs, a, E or 
c peptide as the phosphate acceptor but not GS peptide. 
There was minimal activity on histone 111s or GS pep- 
tide evoked by Ca2+ alone, however, the pseudosub- 
strate site peptides (a, E and 6 peptide) were thio- 
phosphorylated by approximately 3.5-fold of basal ac- 
tivity in the presence of Ca2’. PDBu-evoked activity was 
augmented in the presence of Ca2’ with histone 111s GS 
peptide and c peptide, but this was not the case with CI 
and E peptides although they were extremely efficient 
substrates in terms of counts incorporated. 
4. DISCUSSION 
3.2.3. Kinase substrates 
Various PKC substrates were examined to assess fur- 
Western blots of both aT3-1 whole cell extracts and 
of partially-purified cytosolic PKCs revealed the pres- 
ence of the PKC isoforms a, E and c. We did not detect 
PKCj?, -y, -6 and -11, although this is, of course, depend- 
October 1993 
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Fig. 1. Protein kinase C isoform immunoreactivity of aT3-1 cells. (a) One-dimensional SDS-PAGE followed by Western immunoblotting with PKC 
isoform-specific antisera was performed as described in section 2. Each left lane contains whole male rat brain (lung for r,~) as positive controls 
for the detectable immunoreactivities. Analyses of whole uT3-1 cells revealed etectable amounts of PKCs cc, E and c, whereas /?, y, 6 and q could 
not be detected under the present conditions, even after gross autoradiographic overexposure. The arrows indicate the specific bands. (b) To confirm 
the specificity of staining of aT3-1 cell extracts, antisera were pre-incubated (15 min, 20°C) with (+) and without (-) the appropriate peptide antigen 
(1 &ml). 
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Concentration-response curves for PKC activators on kinase 
activity from partially-purified aT3-1 cell cytosol. Phorbol12,13-dibu- 
tyrate (a), mezerein (b) and DOG (c) were included in the kinase assay 
either in the effective absence of Ca*’ (c3 nM) (0) or presence of Ca*’ 
(100 PM) (e) and concentration-response curves constructed. Values 
(mean f S.E.M. n = 4-6) are expressed as a percentage of that ob- 
tained with a maximally effective dose of PDBu in the presence of 100 
PM Ca*’ (a positive control included within each assay) after subtrac- 
tion of an assay blank (= activity with PS alone, no Ca*’ or activator). 
In calculations of the ECSo values, activities measured in the presence 
of exogenous Ca*+ were not stripped of activity measured in the pres- 
ence of EGTA (‘3 nM free Ca”) before curve fitting as there was 
recruitment of Ca”-dependent PKC activity into the Ca”-independ- 
ent activity with some diterpenes (see section 4). 
ent on the characteristics of the antibodies used and 
concentrations below our detection limits may be pres- 
ent. Futhermore it is possible that expression of PKC 
isozymes may depend on the conditions under which the 
cells are cultured. Thus, it is likely that the activities we 
have characterized in the kinase assay will reflect pre- 
dominantly the presence of the Ca2’-dependent, c1 
isoform, and the Ca2+-independent E and c isoforms. It 
is possible that other newly-described isoforms such as 
8 and ;Z may also be present. 
For all three activators used in this study the total 
activity evoked by an activator in the presence of Ca” 
was similar. Both mezerein and PDBu had EC,, values 
of the same order. The potency of DOG, whilst lower 
than that of the diterpenes, was greater than we have 
recorded for this compound using PKC from some tis- 
sue sources rich in PKCa such as lung and COS 7 cells, 
but not as potent as when using PKCcl purified from 
brain tissue [24]. It is possible that post-translational 
modifications of PKCa may give rise to the differing 
potencies seen in these tissues [24]. In the absence of 
Ca2+, mezerein was approximately 3 times more potent 
than PDBu at evoking kinase activity and, under these 
conditions, mezerein recruited 90% of the total activity 
at the highest concentrations used. In the absence of 
Ca2’ DOG was again less potent than the two diter- 
penes. In other tissues it appears that DOG, even at 
high concentrations, may not activate cPKCs in the 
absence of Ca2’ [24]. If this finding were extrapolated 
to the present study, the percentage of maximum activ- 
ity evoked by DOG in the absence of Ca2’ (i.e. 65 ? 4%) 
may reflect the contribution of nPKCs to the total his- 
tone thiophosphorylation. 
Thiophosphorylation by PKCE may account for 
much of the activator induced activity in the absence of 
Ca2’. However, the data with activators was mainly 
obtained using histone 111s as the phosphate acceptor 
(Fig. 2), which is thought to be a relatively poor sub- 
strate for PKCE [25]. Other candidates for this activity 
are PKCC and/or PKCcl activated in a Ca2+-independ- 
ent fashion which, as indicated above, was certainly 
happening at least with the higher concentrations of 
mezerein. Alternatively, there may be a contribution by 
either PKCXM or an as yet unknown PKC. It is gener- 
ally considered that PKCC does not bind phorbol esters 
and become activated by them [26-301. Certainly the 
original cloned PKCC sequence [26] had only one puta- 
tive phorbol ester binding site and showed no such ac- 
tivity. However, mutant constructs of PKC with only 
one putative binding domain do show some affinity for 
phorbol esters [31]. There have been reports that in 
some tissues PKCC can be translocated from cytosol to 
either the membrane or the nucleus by phorbol esters 
and/or Ca2’ mobilizing receptors [30,32], although the 
question of specificity of the antibody used is critical. 
A large component of basal activity using histone 111s 
and a, E and c peptide (but not GS peptide) as substrate 
was inhibited by the kinase inhibitors used in this study. 
One source of constitutively active thiophosphorylation 
would be cleaved catalytic fragments of PKC, however 
no specific bands of PKC immunoreactivity at low mo- 
lecular weights were detected and the salt elution used 
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on the DEAE column should eliminate such fragments 
from the eluate [33]. Alternatively, PKCC is reported to 
be constitutively active [26] and E peptide in particular 
is reported to be a good substrate for PKCC compared 
with a peptide very similar to GS peptide, that is syntide 
2 [28]. In addition, the ability of K252a to inhibit PKCC 
more potently compared with other isoforms has been 
reported elsewhere [27] and this may be reflected in the 
potency of K252a on basal activity measured in this 
study. These data suggest that constitutively-active 
PKCy [26] may be responsible for some or all of the 
PKC inhibitor-sensitive portion of the basal kinase ac- 
tivity, although a contribution from other unknown ki- 
nases cannot be excluded. 
The partically-purified extract from aT3-1 cytosol 
was able to thiophosphorylate E peptide particularly 
efficiently in the presence of an activator, possibly re- 
Betting the abundance of PKCE in these cells. However, 
it has been shown that PKCa is active on this substrate 
as well [20]. Koide et al. [20] also showed that both 
PKCa and PKCE can effectively phosphorylate a and 
c peptides. Thus the different pseudosubstrate peptides 
do not clearly differentiate PDBu-induced activity of 
the different isoforms. As has been reported previously 
[14,34] and as is illustrated here, some substrate pep- 
tides have less dependence on Ca*’ for PDBu-induced 
activation of cPKCs than histone 111s (or GS peptide). 
The IC,, values obtained in our inhibitor studies for 
either basal, PDBu-evoked or PDBu + Ca”-evoked ac- 
tivity are in agreement with several other reports of the 
potency of some of these inhibitors on the c, E and a 
isoforms, respectively [22,27,35]. Our I&,, values for H7 
also reflect the spectrum of IC,, values that we have 
Table I 
I&, values for various kinase inhibitors on basal, PDBu-evoked and 
PDBu + Ca*‘-evoked histone thiophosphorylation in the presence of 
PS 
I& values 
Inhibitor Basal PDBu PDBu+Ca” 
H7 01M) 66 +- 29 38 f 18 20 + 4 
K252a (uM) 1.8 f 0.4 10.0 + 3.2 3.1 * 1.0 
Ro 31-8220 (nM) 3034 + 161 191 f 13 113 + 11 
Staurosporine (nM) 249 t 23 96 f 77 198 + 70 
GF 109203X (nM) 784 + 339 443 f 135 272 f 83 
Basal ICsO values were assessed irectly from the data, and values 
obtained from the curve fitted to the basal data were stripped from 
the PDBu (1 PM)-evoked data before assessing the IC,, value for this 
fraction of the activity. The I&, value for the PDBu+Ca” (100 PM)- 
evoked activity was obtained after subtracting the values for the un- 
modified PDBu-evoked activity. Values are means It S.E.M. (n = 46) 
at each point on the curves from which IC,, values were calculated. 
found in several physiological models that involve go- 
nadotrophs [7,3638], with the exception of PDBu (100 
nM)-induced LH secretion, which is particularly sensi- 
tive to H7 (ICY,,, value 1.7 + 1.5 PM) [7]. A PKC species 
with such high sensitivity to H7 has been detected by us 
in other tissues, i.e. rat midbrain [39]. Since we did not 
observe a component of PDBu-induced activity with 
such high sensitivity to H7 in aT3-1 cells, we conclude 
that either the PKC isoform that is sensitive to H7 has 
not been expressed in our cells or that this activity is 
masked by a more abundant and less sensitive form. 
Interestingly, the characteristically high IC,, value for 
'ri 
5 800 
- .- 
$5 
2 2 
0 
600 
rC 
OP 
Q) 8 400 i 
basal H7 PDBu Ca *+ PDBu+Ca *+ 
Fig. 3. Kinase activation or inhibition with various substrates. Histone 111s (open bars), GS peptide (diagonal hatched bars), TV peptide (broken 
cross-hatched bars), E peptide (closed bars) and [ peptide (horizontal-hatched bars) were used as phosphate acceptors with either no drug (basal), 
H7 (300 PM), Ca*+ alone (100 PM), PDBu (1 PM) or PDBu + Ca*‘. Substrate concentrations were 1.25 mg/ml for histone, 50 PM for the 
pseudosubstrate site peptides and 100 PM for GS peptide. Significance of differences between means was assessed using the Student’s t-test on the 
untransformed ata (* P < 0.05, ** P < 0.01 compared with basal values; +P < 0.05, ++P c 0.01 compared with PDBu alone values, mean i: S.E.M., 
n=46). 
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H7 on basal kinase activity here is very similar to the 
profile of inhibition for LHRH self-priming [9]. Al- 
though phorbol esters can elicit release and increased 
responsiveness in gonadotrophs, they do not induce the 
LHRH priming phenomenon [40]. If the basal PKC-like 
activity here does result from phorbol ester-insensitive 
PKCC, the intriguing possibility exists that PKCC may 
be involved in this physiological event. 
In summary, the kinase activity in aT3-1 cell cytosol 
was characterized with activators, and both Ca2+-de- 
pendent and -independent PDBu-evoked activity were 
observed with histone 111s as substrate. In addition, a 
constitutively-active PKC-like kinase activity was de- 
tected using a variety of PKC inhibitors. These activities 
may be related predominantly to the characteristics of 
the cPKCa, the nPKC.c and atypical PKC[, respec- 
tively, whose presence was confirmed by Western blot- 
ting. The distinctive inhibition characteristics observed 
in components of the kinase activity are reflected in 
different aspects of cellular regulation in pituitary cells 
(including gonadotrophs) [7,9,36-391, implying distinct 
roles of the different isoforms of PKC. 
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